With a market cap of\u00a0$16.8 billion, Hologic, Inc. (HOLX) is a global medical technology company focused on developing and supplying diagnostic products, medical imaging systems, and surgical solutions for women\u2019s health. It operates through four main segments: Diagnostics, Breast Health; GYN Surgical; and Skeletal Health, offering a wide range of tools for early detection, diagnosis, and treatment.<\/p>\n
Companies valued at $10 billion or more are generally labeled as \u201clarge-cap\u201d stocks, and Hologic fits this criterion perfectly. The company distributes its products worldwide through direct sales teams, distributors, and representatives.<\/p>\n
Shares of the Marlborough, Massachusetts-based company have fallen marginally from its\u00a052-week high of $75.75. HOLX stock\u00a0has risen marginally over the past three months, surpassing the broader\u00a0Dow Jones Industrials Average’s ($DOWI) 2% drop over the same time frame.<\/p>\n HOLX stock is up marginally on a YTD basis, outpacing Dow Jones’ 2.2% decrease. Longer term, shares of the medical device maker have increased 21% over the past 52 weeks, compared to\u00a0DOWI\u2019s 13% return over the same time frame.<\/p>\n The stock has been trading above its 50-day moving average since late May 2025. Also, it has moved above its 200-day moving average since August 2025.<\/p>\n Shares of Hologic fell marginally following its\u00a0Q1 2026 results on Jan. 29. Adjusted EPS came in at $1.04 and revenue totaled $1.05 billion,\u00a0both below expectations. Investor sentiment was further pressured by weakness in Diagnostics revenue, margin compression from $15.3 million in tariff-related costs, and the company\u2019s decision not to provide forward guidance due to its pending acquisition by Blackstone and TPG.<\/p>\n In comparison, rival The Cooper Companies, Inc. (COO) has lagged behind HOLX stock. COO stock\u00a0has declined 13.2% on a YTD basis and 11.2% over the past 52 weeks.<\/p>\n Despite HOLX\u2019s outperformance, analysts remain cautious about its prospects. Among the 18 analysts covering the stock, there is a consensus rating of \u201cHold,\u201d and\u00a0the mean price target of $75.58 suggests a marginal premium to current levels.<\/p>\n On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>